Author Question: Which of the following constitutes a threat to the internal validity of within subjects factorial ... (Read 70 times)

eruditmonkey@yahoo.com

  • Hero Member
  • *****
  • Posts: 546
Which of the following constitutes a threat to the internal validity of within subjects factorial designs?
 
  a. testing c. history
  b. the carryover effect d. all of these

Question 2

In a within subjects design, _____.
 
  a. each subject is his or her own control
  b. subjects are randomly assigned to conditions
  c. subjects experience only one level of the treatments
  d. all of these



nmyers

  • Sr. Member
  • ****
  • Posts: 336
Answer to Question 1

D
The internal validity of the within subjects factorial design is threatened by all of factors that threaten the simple within subjects designs (e.g., testing, maturation, and history). In addition, the carryover effect poses a threat to within subjects factorial designs.

Answer to Question 2

A
Within subjects means that each subject serves as his or her own control. In a between subjects design, participants are randomly assigned to experience only one level of the treatment.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

The modern decimal position system was the invention of the Hindus (around 800 AD), involving the placing of numerals to indicate their value (units, tens, hundreds, and so on).

Did you know?

Russia has the highest death rate from cardiovascular disease followed by the Ukraine, Romania, Hungary, and Poland.

Did you know?

Approximately 70% of expectant mothers report experiencing some symptoms of morning sickness during the first trimester of pregnancy.

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library